Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.66, $0.20 better than the analyst estimate of $0.46 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Earnings Guidance Hot Earnings Hot Guidance Trading Halts

Credit Suisse Upgrades Myriad Genetics (MYGN) to NeutralFebruary 7, 2014 6:50 AM Ladenburg Thalmann Downgrades Myriad Genetics (MYGN) to NeutralFebruary 5, 2014 8:17 AM JMP Securities Upgrades Myriad Genetics (MYGN) to Market PerformFebruary 5, 2014 6:56 AM Myriad Genetics (MYGN) to Acquire Crescendo Bio in $270M DealFebruary 4, 2014 4:04 PM Myriad Genetics, Inc. (MYGN) trading halted with news pendingFebruary 4, 2014 4:01 PM